Using subclass mapping, we compared the transcriptome profiles of two GC subclasses separated by FRLSG with another published dataset containing 47 patients with melanoma who received anti-PD-1 and anti-CTLA4 immunotherapy treatment. The gene discussed is CTLA4; the disease is melanoma.